Research Keyword: antifungal agents

Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multiple cyp51 isozyme genes

mycolabadmin

This study found that different azole antifungal drugs work better against different versions of an enzyme (Cyp51) that fungi need to survive. By combining two azole drugs that each target different enzyme versions, researchers achieved stronger antifungal effects than either drug alone. This discovery suggests a new strategy for treating stubborn fungal infections by carefully selecting drug combinations based on which enzyme versions the fungus possesses.

Read More »

Favourable outcome of Fusarium prosthetic valve endocarditis in a patient with an Ebstein anomaly

mycolabadmin

A 26-year-old woman with a congenital heart condition (Ebstein anomaly) received a replacement heart valve. Six months later, a rare fungal infection caused by Fusarium developed on the new valve, leading to lung complications. Through a combination of surgery to remove the infected valve and antifungal medications, particularly voriconazole, the patient recovered successfully. This case demonstrates that even life-threatening fungal heart infections can be treated with proper surgical intervention and targeted medication.

Read More »

Fungal Δ9-fatty acid desaturase: a unique enzyme at the core of lipid metabolism in Aspergillus fumigatus and a promising target for the search for antifungal strategies

mycolabadmin

Certain dangerous fungal infections like aspergillosis are difficult to treat because current antifungal drugs have significant side effects or the fungi are developing resistance. Scientists have discovered that a specific enzyme called Δ9-fatty acid desaturase, which fungi need to make fats for their cell membranes, has a unique structure different from human cells. This structural difference offers a new opportunity to design antifungal drugs that could kill fungi without harming human cells, potentially providing safer and more effective treatments for serious fungal infections.

Read More »

Antimicrobial and Antifungal Activities of Proline-Based 2,5-Diketopiperazines Occurring in Food and Beverages and Their Synergism with Lactic Acid

mycolabadmin

Researchers synthesized special cyclic peptides called 2,5-diketopiperazines (found naturally in fermented foods like bread and cheese) and tested their ability to kill harmful molds and bacteria. When combined with lactic acid (a natural preservative), these compounds worked extremely well together, achieving nearly complete mold inhibition. This research suggests that using special starter cultures that naturally produce these compounds could help keep food fresh longer without artificial preservatives.

Read More »

Functional diversification of epidithiodiketopiperazine methylation and oxidation towards pathogenic fungi

mycolabadmin

This research shows that Trichoderma hypoxylon, a beneficial fungus used in agriculture, produces different versions of antifungal compounds called epidithiodiketopiperazines (ETPs) to fight various harmful fungi. By deleting genes responsible for modifying these compounds, scientists found that different modifications work better against different pathogens—some modifications are more effective against mold fungi while others work better against grain pathogens. This demonstrates that the fungus uses chemical diversity as a strategy to protect crops from multiple threats.

Read More »

Engineered biosynthesis and characterization of disaccharide-pimaricin

mycolabadmin

Scientists successfully created a genetically engineered bacterium that produces a safer version of an antifungal drug called pimaricin. The new version, called disaccharide-pimaricin, dissolves much better in water and causes significantly less damage to human blood cells, making it a much safer option for treating fungal infections. Although it’s slightly less effective at killing fungi, the improvement in safety and solubility makes it a promising candidate for treating eye infections and other fungal diseases.

Read More »

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections that can occur in people with weakened immune systems. This research review looked at three clinical trials comparing isavuconazole to other antifungal drugs and found it works just as well while being easier on the liver. Notably, isavuconazole caused fewer drug-related side effects and liver problems compared to voriconazole, another common antifungal drug.

Read More »
Scroll to Top